Interlace Medical Inc. raised nearly $21 million to begin commercializing its MyoSure minimally invasive system to remove intrauterine fibroids and polyps with an outpatient treatment.
The Framingham-based company raised the Series C round from Baird Venture Partners, Boston-based HLM Venture Partners, Hambrecht & Quist Capital Management LLC and Aperture Venture Partners.
Previous investors New Leaf Venture Partners and Newton-based Spray Venture Partners also participated in the round, which was valued at $20.5 million.